Castle Biosciences (CSTL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Executive summary
Annual meeting scheduled for May 28, 2026, at the San Luis Resort, Galveston, Texas, with voting available online, by mail, or in person.
Record date for voting eligibility set as April 1, 2026.
Voting matters and shareholder proposals
Election of three Class I director nominees to serve until the 2029 annual meeting: Ellen Goldberg, Miles D. Harrison, and Tiffany P. Olson.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory approval of named executive officer compensation (say-on-pay).
Approval of non-employee director compensation policy.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director elections and compensation policies.
Proxy holders have discretionary authority to vote on substitute nominees if any nominee is unable or unwilling to serve.
Latest events from Castle Biosciences
- Q3 2024 revenue up 39% to $85.8M, guidance raised on strong test adoption and profitability.CSTL
Q3 20248 Jul 2026 - Q1 revenue up 21%, guidance raised, Previse acquired, IDgenetix discontinued, SCC risk remains.CSTL
Q1 20258 Jul 2026 - Q2 revenue up 74% to $87M; guidance raised to $275–300M on strong growth and margin gains.CSTL
Q2 20248 Jul 2026 - Raised 2026 guidance after strong Q1 growth and expanded diagnostic test adoption.CSTL
Jefferies Global Healthcare Conference 20263 Jun 2026 - Q1 2026 revenue hit $83.7M, core test volumes rose 36%, and guidance increased to $345–355M.CSTL
Q1 20267 May 2026 - Strong clinical evidence and financial growth support expansion and pipeline innovation.CSTL
Corporate presentation6 May 2026 - Genomic testing enables precise SLNB decisions and improved melanoma outcomes.CSTL
Status update29 Apr 2026 - 2025 saw record revenue, strong governance, and enhanced compensation and ESG policies.CSTL
Proxy filing8 Apr 2026 - 2025 revenue hit $344.2M with 37% core test growth and strong cash reserves.CSTL
Q4 202526 Feb 2026